Emily Pharr, MD
Neurology · Bozeman, MTNPI 1104009745
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $11,836 of the $14,091 with a category attached, or 84.0%. Biogen accounts for 91.7% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2019 at $7,205 and has fallen 88.5% since, to $829 in 2025.
Across 53 payments — averaging $265.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$13K
- AstraZeneca$396
- Teva Pharmaceuticals USA, Inc.$208
- Pfizer$121
- AbbVie$109
- Argenx US, Inc.$83
- plus $251 from 7 others
Across 126 payments — averaging $4614.02 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi$256K
- Genentech, Inc.$243K
- Biogen$28K
- Novartis$27K
- EMD Serono, Inc.$15K
- Alkermes, Inc.$8K
- plus $5K from 2 others
What the payments were for
- Consulting fees$11,83684%
- Travel & lodging$7966%
- Food & beverage$1,2829%
- Education$1781%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biogen | 13 | $12,925 |
| AstraZeneca | 6 | $396 |
| Teva Pharmaceuticals USA, Inc. | 8 | $208 |
| Pfizer | 7 | $121 |
| AbbVie | 4 | $109 |
| Argenx US, Inc. | 3 | $83 |
| Bristol Myers Squibb | 3 | $48 |
| Genentech, Inc. | 1 | $48 |
| Genentech USA, Inc. | 2 | $39 |
| Ipsen Biopharmaceuticals, Inc | 1 | $35 |
| Novartis | 2 | $34 |
| E.r. Squibb & Sons, L.L.C. | 2 | $30 |
| Lilly USA, LLC | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,091 in reported general payments places this provider in the 85th percentile of 48 neurology providers in Montana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Kesimpta PenOfatumumab | 67 | $574,349 |
| TecfideraDimethyl Fumarate | 15 | $219,482 |
| CopaxoneGlatiramer Acetate | 26 | $190,260 |
| Avonex (4 Pack)Interferon Beta-1a | 22 | $181,277 |
| BetaseronInterferon Beta-1b | 16 | $155,809 |
| VumerityDiroximel Fumarate | 12 | $104,498 |
| Glatiramer Acetate | 23 | $38,798 |
| GlatopaGlatiramer Acetate | 12 | $24,633 |
| Teriflunomide | 29 | $18,625 |
| FingolimodFingolimod Hcl | 12 | $17,780 |
| Dalfampridine ErDalfampridine | 79 | $16,795 |
| MyrbetriqMirabegron | 18 | $13,328 |
| Dimethyl Fumarate | 86 | $11,871 |
| Gabapentin | 178 | $4,914 |
| Baclofen | 89 | $2,186 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BiogenTecfidera, Avonex (4 Pack), Vumerity | $12,925 | $505,25749 claims |
| Teva Pharmaceuticals USA, Inc.Copaxone | $208 | $190,26026 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 48 neurology providers in Montana.
Other neurology in Bozeman
- Mario PizziniBozeman$3K
- David LoranceBozeman$534
- Matthew BainBozeman$200
- James RaglandBozeman$194
- Richard PopwellBozeman$62
- Joshua KnappenbergerBozeman$51
- Ann CollierBillings$164K
- Dennis DietrichGreat Falls$140K
- Nicole ClarkHelena$85K
- Kristian FrenchBillings$64K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.